Talking to a GP or dietitian with your report
A consumer microbiome PDF is supplementary context for gut symptoms, not a primary diagnostic test in NHS or most EU primary-care pathways. Useful appointments pair symptom chronology and clinical red-flag exclusion with report metadata (lab, method, date, medications), while deprioritising proprietary “health scores” that lack assay validation.
Clinicians vary in familiarity with metagenomics. Your job is to translate report language into questions they can answer (Do I need calprotectin? Is low-FODMAP appropriate? Could this be coeliac disease?) rather than demanding treatment for each low taxon.
For report mechanics: Reading your microbiome report. For urgency symptoms: Red flags.
What clinicians typically find useful
Bring a one-page summary plus the full PDF:
| Item | Why it matters |
|---|---|
| Main symptoms (onset, frequency, blood, weight change) | Drives Rome vs alarm pathway |
| Bristol stool chart pattern | IBS subtype context |
| Diet trials already tried (FODMAP, gluten, fibre) | Avoids duplicate advice |
| Medications (PPI, antibiotics, metformin, opioids) | Known microbiome confounders (Medications) |
| Report method, 16S vs shotgun metagenomics | Resolution limits for taxa |
| Lab name and collection date | Reproducibility |
| Concurrent probiotics/supplements | Explains recent taxa spikes |
| Pregnancy, paediatric, or immunosuppression | Changes risk calculus |
Validated tests clinicians recognise:
- Faecal calprotectin, inflammation screen (Calprotectin)
- Coeliac serology
- FIT / faecal immunochemical test for colorectal screening programmes
- H. pylori breath or stool antigen when dyspepsia present
- Coeliac, thyroid, coeliac mimics per presentation
Offer: “I’d like your view on whether this report adds anything beyond standard workup for my symptoms.”
What to deprioritize in the appointment
| Report element | Why clinicians push back |
|---|---|
| ”Optimal range” traffic lights | Often vendor cohort percentiles, not clinical reference intervals |
| Dysbiosis index | No standardised definition (Dysbiosis) |
| Sequencing inflammation score | Unvalidated vs calprotectin (Gut inflammation markers) |
| Long opportunistic bacteria lists | Contaminants and oral taxa on 16S |
| Supplement product names embedded in PDF | Perceived commercial bias |
| SIBO diagnosis from stool | Geography mismatch, breath testing |
Do not open with: “My Akkermansia is low, what should I buy?” Lead with symptoms and ask whether dietitian referral or calprotectin is appropriate.
If the clinician dismisses the report entirely, you can note: “I understand it’s not diagnostic; I’m looking for help integrating symptoms with whether a low-FODMAP trial or probiotic is reasonable.”
Questions to ask
For your GP:
- Do my symptoms meet Rome IV IBS criteria or are alarm features present?
- Should I have calprotectin, coeliac serology, or thyroid tests before changing diet?
- Is referral to gastroenterology or dietitian indicated?
- How do my medications explain report findings?
- If I trial a probiotic, is there a strain you recommend for my symptom pattern?
For a dietitian (FODMAP-experienced):
- Is a low-FODMAP elimination appropriate for my symptoms and nutritional needs?
- How do I avoid over-restriction and reintroduce systematically?
- Can you review my fibre intake and meal timing (Meal patterns)?
- How does this interact with pregnancy / paediatric needs if relevant?
For yourself (shared decision-making):
- What would I do differently if I did not have this report?
- Which report lines have clinical biomarker equivalents?
- Am I trying to replace medical tests with sequencing?
UK/EU vs direct-to-consumer context
| Aspect | UK / NHS typical frame | Direct-to-consumer report |
|---|---|---|
| Funding | Calprotectin, coeliac tests guideline-based | Consumer pays for sequencing |
| Regulation | CE-marked IVDs for clinical tests | Wellness / research framing common |
| Dietetics | NHS dietitian referral pathways; FODMAP-trained availability variable | Monash app + private dietitians |
| Data protection | NHS record governance | Private lab privacy policies |
| Role of microbiome | Adjunct research tool in IBD centres | Mass-market “optimisation” narrative |
EU IVDR and UK UKCA/CE frameworks regulate clinical diagnostics; many DTC kits operate outside traditional clinical pathways, that does not make them worthless, but it does mean GPs are not trained to treat vendor percentiles as NHS lab results.
Private functional medicine panels may order stool PCR and calprotectin alongside sequencing, still interpret combinations via multi-marker synthesis, not single scores.
What not to conclude
- Clinicians must not be expected to prescribe from vendor optimal ranges.
- A normal calprotectin overrides a red sequencing inflammation flag for IBD screening decisions.
- Dietitians will not endorse every commercial panel’s supplement appendix.
- Shared decision-making means you can decline low-value retesting as well as accept useful trials.